<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846803</url>
  </required_header>
  <id_info>
    <org_study_id>BIrUTI</org_study_id>
    <nct_id>NCT04846803</nct_id>
  </id_info>
  <brief_title>Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment</brief_title>
  <acronym>BIrUTI</acronym>
  <official_title>Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It&#xD;
      affects 150 million people annually. Treatment of patients with UTI entails a high&#xD;
      consumption of antibiotics and large social and health costs. With this protocol, we want to&#xD;
      elucidate alternative treatment methods for especially recurrent urinary tract infection.&#xD;
      Bacteria have internal competitiveness (bacterial interference) and it is known that the&#xD;
      non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.&#xD;
&#xD;
      We intend to strengthen the clinical evidence that it can be used as patient treatment&#xD;
      through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It&#xD;
      affects 150 million people annually. Treatment of patients with UTI entails a high&#xD;
      consumption of antibiotics and large social and health costs. With this protocol, we want to&#xD;
      elucidate alternative treatment methods for especially recurrent urinary tract infection.&#xD;
      Bacteria have internal competitiveness (bacterial interference) and it is known that the&#xD;
      non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.&#xD;
&#xD;
      We intend to strengthen the clinical evidence that it can be used as patient treatment&#xD;
      through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.&#xD;
&#xD;
      Claim to be investigated:&#xD;
&#xD;
        -  The non-pathogenic bacterial strain (ABU) E.coli can overcome the most common pathogenic&#xD;
           E.coli (UPEC) in humans.&#xD;
&#xD;
        -  ABU can be used for preventive treatment in patients with recurrent urinary tract&#xD;
           infections.&#xD;
&#xD;
      Clinical effect of preventive treatment (prophylactic treatment) with the non-pathogenic&#xD;
      bacterial strain (ABU) in a selected group of patients with recurrent cystitis: A clinical,&#xD;
      placebo-controlled, double-blind safety study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The treatment is blinded to the investigator in a ratio 3:1&#xD;
Patients with prophylactic bladder flushing with an ABU strain.&#xD;
The control group with bladder flushing with saline solution.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first symptomatic UTI after the intervention</measure>
    <time_frame>1 year</time_frame>
    <description>Symptoms and the need for medical treatment or hospitalisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of events (symptomatic UTIs) in the follow-up period</measure>
    <time_frame>1 year</time_frame>
    <description>The number of prescriptions or hospital visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life by standard Questionnaires_ICIQ-LUT</measure>
    <time_frame>1 year</time_frame>
    <description>ICIQ-LUTSqol 08/04 questionnaire evaluating quality of life (QoL) in urinary incontinent patients (overall score with greater values indicating increased symptom severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by standard Questionnaires_KAD</measure>
    <time_frame>1 year</time_frame>
    <description>ICIQ-LTCqol 12/12 Living with a long term catheter (overall score with greater values indicating increased symptom severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by standard Questionnaires_SF36</measure>
    <time_frame>1 year</time_frame>
    <description>SF-36 (scored so that a high score defines a more favorable health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Hospital visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications (bleeding, pain)</measure>
    <time_frame>1 year</time_frame>
    <description>Complications due to bladder lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological diagnostics: Etiology, resistance</measure>
    <time_frame>1 year</time_frame>
    <description>Measurements during treatment protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Para-clinical findings: CRP, leukocytes, U-stix, renal function (creatinine</measure>
    <time_frame>1 year</time_frame>
    <description>Measurements during treatment protocol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sexual function</measure>
    <time_frame>1 year</time_frame>
    <description>ICIQ-FLUTSsex or ICIQ-MLUTSsex evaluation of female/male sexual matters associated with their lower urinary tract symptoms and impact on quality of life (overall score with greater values indicating increased symptom severity)</description>
  </other_outcome>
  <other_outcome>
    <measure>Continence_UI</measure>
    <time_frame>1 year</time_frame>
    <description>ICIQ-UI SF evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence (overall score with greater values indicating increased symptom severity)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lower Urinary Tract Disease</measure>
    <time_frame>1 year</time_frame>
    <description>ICIQ-FLUTS LF or ICIQ-MLUTS LF questionnaire for detailed evaluation of female/male lower urinary tract symptoms and impact on quality of life (overall score with greater values indicating increased symptom severity)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Recurrent Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Patients prophylatic treated with ABU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with prophylactic bladder flushing with an ABU strain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group with bladder flushing with saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABU bladder lavage</intervention_name>
    <description>Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)</description>
    <arm_group_label>Patients prophylatic treated with ABU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline bladder lavage</intervention_name>
    <description>Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline</description>
    <arm_group_label>Patients control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with recurrent cystitis including 2 times of rUTI within the last 6 months&#xD;
             or 3 times in the last 12 months, where at least 2 cultures show the same bacteria.&#xD;
&#xD;
          -  Normal investigation for lower urinary tract diseases (LUTD) including voiding diary,&#xD;
             symptom scores, flexible cystoscopy, voiding diagram and test for residual urine.&#xD;
&#xD;
          -  Failed previously treatments.&#xD;
&#xD;
          -  Patients with native bladder with both spontaneous voiding, the need for clean&#xD;
             intermittent catheter (CIC) or indwelling catheter.&#xD;
&#xD;
          -  Patients with neurogenic and non-neurogenic bladder dysfunction.&#xD;
&#xD;
          -  Patients with urostomy, kidney transplantation or another complicated genesis.&#xD;
&#xD;
          -  Written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy in the urinary tract, kidney-, ureteral- or bladder stones, age &lt; 18 years,&#xD;
             pregnancy, breastfeeding. Patients in ongoing orally antibiotic treatment. Not able to&#xD;
             speak or understand Danish.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karin Andersen, MD</last_name>
    <phone>+45 21570468</phone>
    <email>karin.andersen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Lund, Prof.</last_name>
    <email>lars.lund@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense university hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Karin Andersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>rUTI</keyword>
  <keyword>E.coli</keyword>
  <keyword>prophylactic</keyword>
  <keyword>bladder lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

